We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
TESTIS CANCER - Interactive survival scatter ploti
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red. The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The interactive Survival Scatter plot allows for the cutoff to be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Survival analysis". Under the Survival Scatter plot the p-score landscape is shown together with the difference in median between survival time for patients who have died with respect to high and low expression. This is intended to aid the user in exploring custom cutoffs.
Individual patient data is displayed in an interactive plot and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off).
Based on the FPKM value of each gene, we classified the patients into two groups and examined their prognoses. In the analysis, we excluded genes with low expression, i.e., those with a median expression among samples less than FPKM 1. The prognosis of each group of patients was examined by Kaplan-Meier survival estimators, and the survival outcomes of the two groups were compared by log-rank tests. To choose the best FPKM cut-offs for grouping the patients most significantly, all FPKM values from the 20th to 80th percentiles were used to group the patients, significant differences in the survival outcomes of the groups were examined and the value yielding the lowest log-rank P value is selected.
: 24.01
Median expression: N/A
Median follow up time: N/A P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A 5-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A 5-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average FPKM
23.8
Number of samples
134
Samples
Sample
Description
FPKM
TCGA-2G-AALP-01A
43 years, male, white, stage:iiib, alive, 2645 days
61.6
TCGA-2G-AAL7-01A
32 years, male, white, stage:is, alive, 3991 days
53.4
TCGA-2G-AAGN-01A
41 years, male, white, stage:iiib, alive, 3656 days
48.6
TCGA-2G-AAFN-01A
26 years, male, white, stage:iiib, alive, 773 days
47.0
TCGA-2G-AAG8-01A
21 years, male, white, stage:ib, alive, 2289 days
46.9
TCGA-2G-AAGW-01A
38 years, male, white, stage:is, alive, 4899 days
45.0
TCGA-XY-A8S3-01B
24 years, male, white, stage:is, alive, 843 days
44.8
TCGA-X3-A8G4-01A
33 years, male, white, stage:is, alive, 856 days
42.8
TCGA-2G-AAH0-01A
30 years, male, white, stage:is, alive, 5477 days
41.6
TCGA-YU-AA4L-01A
27 years, male, black or african american, stage:iiic, alive, 1573 days
41.4
TCGA-2G-AAFI-01A
41 years, male, white, stage:ib, alive, 675 days
39.7
TCGA-2G-AAHL-01A
26 years, male, white, stage:i, alive, 7081 days
39.3
TCGA-VF-A8A8-01A
18 years, male, white, stage:ia, alive, 1131 days
38.9
TCGA-2G-AAKH-01A
19 years, male, white, stage:ii, alive, 6862 days
38.4
TCGA-2G-AAGJ-01A
28 years, male, black or african american, stage:ia, alive, 2938 days
37.9
TCGA-2G-AAFO-01A
33 years, male, white, stage:iia, alive, 685 days
37.2
TCGA-2G-AAHT-01A
32 years, male, white, stage:is, alive, 542 days
36.8
TCGA-2G-AAGM-01A
51 years, male, white, stage:is, alive, 3891 days
36.3
TCGA-2G-AAFL-01A
35 years, male, white, stage:ib, alive, 750 days
35.4
TCGA-2G-AAKG-01A
22 years, male, white, stage:i, alive, 6598 days
34.4
TCGA-W4-A7U4-01A
23 years, male, white, alive, 738 days
33.7
TCGA-2G-AAKL-01A
26 years, male, white, stage:ii, alive, 7023 days
33.6
TCGA-2G-AAGC-01A
28 years, male, white, stage:is, alive, 2585 days
33.3
TCGA-2G-AAL5-01A
31 years, male, white, stage:i, alive, 7437 days
33.2
TCGA-2G-AAH4-01A
34 years, male, white, stage:ii, alive, 6210 days
32.7
TCGA-2G-AAG7-01A
33 years, male, white, stage:is, alive, 2475 days
32.7
TCGA-2G-AAGA-01A
38 years, male, white, stage:iia, alive, 2439 days
32.7
TCGA-2G-AAG0-01A
23 years, male, white, stage:is, alive, 1529 days
32.4
TCGA-YU-A90Y-01A
23 years, male, black or african american, stage:iiic, dead, 17 days
32.4
TCGA-VF-A8AD-01A
36 years, male, white, stage:ib, alive, 1006 days
32.1
TCGA-2G-AAKM-01A
14 years, male, white, stage:ii, dead, 6972 days
32.1
TCGA-YU-A90P-01A
25 years, male, white, stage:ia, alive, 2069 days
31.5
TCGA-2G-AAH8-01A
45 years, male, white, stage:iiic, alive, 2248 days
30.5
TCGA-XE-A8H1-01A
24 years, male, white, stage:is, alive, 209 days
30.3
TCGA-W4-A7U3-01A
26 years, male, white, alive, 149 days
29.8
TCGA-2G-AAGF-01A
28 years, male, white, stage:is, alive, 2734 days
29.4
TCGA-SN-A84Y-01A
18 years, male, white, stage:is, alive, 524 days
29.3
TCGA-2G-AAFE-01A
37 years, male, white, stage:iia, alive, 4702 days
29.2
TCGA-XY-A8S2-01A
67 years, male, white, stage:i, alive, 672 days
28.6
TCGA-YU-AA61-01A
29 years, male, white, stage:is, alive, 864 days
28.5
TCGA-2G-AAGO-01A
41 years, male, white, stage:is, alive, 4026 days
28.0
TCGA-4K-AA1G-01A
34 years, male, white, stage:is, alive, 436 days
27.9
TCGA-2G-AAFM-01A
31 years, male, white, stage:iia, alive, 503 days
27.8
TCGA-2G-AAGT-01A
30 years, male, white, stage:is, alive, 4406 days
27.8
TCGA-2G-AAF8-01A
33 years, male, white, stage:ia, alive, 3911 days
27.2
TCGA-XE-AAOD-01A
39 years, male, white, stage:ib, alive, 2058 days
26.7
TCGA-4K-AAAL-01A
31 years, male, white, stage:is, alive, 483 days
26.1
TCGA-2G-AAFV-01A
31 years, male, white, stage:is, alive, 1389 days
25.9
TCGA-2G-AAEW-01A
31 years, male, white, stage:is, dead, 618 days
25.8
TCGA-YU-A912-01A
34 years, male, black or african american, stage:iiic, alive, 866 days
25.4
TCGA-2G-AAFG-01A
30 years, male, white, stage:is, alive, 6183 days
24.9
TCGA-VF-A8AE-01A
39 years, male, white, stage:ia, alive, 727 days
24.9
TCGA-XE-AAOF-01A
50 years, male, asian, stage:ia, alive, 1268 days
24.7
TCGA-2G-AAGK-01A
20 years, male, white, stage:is, alive, 3621 days
24.5
TCGA-XE-AAOB-01A
27 years, male, white, stage:is, dead, 513 days
24.2
TCGA-2G-AAFY-01A
24 years, male, white, stage:iia, alive, 1099 days
23.9
TCGA-2G-AAGE-01A
21 years, male, white, stage:is, alive, 2478 days
23.8
TCGA-2G-AAGY-01A
28 years, male, white, stage:is, alive, 5329 days
23.3
TCGA-2G-AAHN-01A
32 years, male, white, stage:i, alive, 6445 days
23.2
TCGA-2G-AAEX-01A
38 years, male, white, stage:is, alive, 1259 days
22.9
TCGA-2G-AAGI-01A
33 years, male, white, stage:is, alive, 3137 days
22.8
TCGA-2G-AAG9-01A
25 years, male, white, stage:iiib, alive, 2234 days
22.7
TCGA-2G-AAG3-01A
53 years, male, white, stage:is, alive, 1593 days
22.7
TCGA-2X-A9D5-01A
49 years, male, white, stage:i, alive, 435 days
22.6
TCGA-2G-AAKD-01A
18 years, male, white, stage:iii, alive, 6340 days
22.6
TCGA-YU-A94I-01A
66 years, male, stage:ia, alive, 536 days
22.3
TCGA-XE-AAOJ-01A
24 years, male, white, stage:is, alive, 1550 days
22.2
TCGA-SB-A76C-01A
38 years, male, white, alive, 42 days
22.1
TCGA-WZ-A7V3-01A
20 years, male, white, stage:i, alive, 753 days
22.0
TCGA-2G-AAGZ-01A
27 years, male, white, stage:iiia, alive, 5233 days
22.0
TCGA-XY-A9T9-01A
37 years, male, white, stage:is, alive, 281 days
21.9
TCGA-W4-A7U2-01A
26 years, male, white, alive, 1263 days
21.7
TCGA-VF-A8AC-01A
29 years, male, white, stage:ia, alive, 1083 days
21.7
TCGA-WZ-A7V4-01A
28 years, male, white, stage:i, alive, 894 days
21.5
TCGA-2G-AAFZ-01A
32 years, male, white, stage:iii, alive, 1353 days
21.1
TCGA-2G-AAF6-01A
28 years, male, white, stage:is, alive, 3491 days
20.9
TCGA-2G-AAF1-01A
28 years, male, asian, stage:is, alive, 1403 days
20.5
TCGA-VF-A8A9-01A
31 years, male, white, stage:ia, alive, 1119 days
20.3
TCGA-WZ-A8D5-01A
38 years, male, white, alive, 774 days
20.1
TCGA-2G-AAH2-01A
20 years, male, white, stage:is, alive, 6060 days
19.9
TCGA-XE-A8H5-01A
29 years, male, stage:is, alive, 1217 days
19.7
TCGA-2G-AAGP-01A
33 years, male, white, stage:iia, alive, 4018 days
19.7
TCGA-2G-AAGS-01A
39 years, male, white, stage:iiib, alive, 4816 days
19.5
TCGA-4K-AA1I-01A
26 years, male, white, stage:ia, alive, 3 days
19.4
TCGA-2G-AAFJ-01A
23 years, male, asian, alive, 792 days
19.0
TCGA-XE-AAO4-01A
40 years, male, white, stage:ia, alive, 367 days
18.8
TCGA-SB-A6J6-01A
22 years, male, white, stage:ia, alive, 413 days
18.7
TCGA-WZ-A7V5-01A
27 years, male, white, stage:i, alive, 1061 days
18.7
TCGA-ZM-AA0B-01A
32 years, male, white, stage:ia, alive, 838 days
18.3
TCGA-YU-A94D-01A
28 years, male, stage:iiib, alive, 2167 days
18.3
TCGA-2G-AAHP-01A
31 years, male, white, stage:is, alive, 5667 days
18.2
TCGA-SN-A84X-01A
21 years, male, white, stage:is, alive, 312 days
18.2
TCGA-XE-AAO6-01A
47 years, male, white, stage:ia, alive, 240 days
18.1
TCGA-VF-A8AA-01A
51 years, male, white, stage:i, alive, 1146 days
18.1
TCGA-XE-A8H4-01A
23 years, male, white, stage:ia, alive, 559 days
18.1
TCGA-SN-A6IS-01A
26 years, male, white, stage:is, alive, 496 days
17.8
TCGA-SN-A84W-01A
30 years, male, white, stage:is, alive, 293 days
17.8
TCGA-YU-A90Q-01A
21 years, male, stage:ib, alive, 1964 days
17.7
TCGA-XE-AAO3-01A
33 years, male, asian, stage:i, alive, 2857 days
17.6
TCGA-XE-AANJ-01A
39 years, male, white, stage:is, alive, 2007 days
17.3
TCGA-XY-A89B-01A
35 years, male, white, stage:ia, alive, 471 days
17.2
TCGA-XE-AANR-01A
24 years, male, white, stage:i, alive, 14 days
17.0
TCGA-2G-AAHG-01A
25 years, male, white, stage:i, alive, 1819 days
16.6
TCGA-XE-AANI-01A
37 years, male, white, stage:is, alive, 1041 days
16.4
TCGA-2G-AAGG-01A
20 years, male, white, stage:iiic, alive, 2611 days
16.1
TCGA-SO-A8JP-01A
29 years, male, white, stage:i, alive, 540 days
16.0
TCGA-S6-A8JW-01A
37 years, male, white, stage:is, alive, 698 days
15.9
TCGA-2G-AAHC-01A
33 years, male, white, stage:is, alive, 5539 days
15.6
TCGA-2G-AAHA-01A
48 years, male, white, stage:ib, alive, 3349 days
15.3
TCGA-XE-A9SE-01A
35 years, male, white, stage:ia, alive, 708 days
15.1
TCGA-VF-A8AB-01A
31 years, male, black or african american, stage:ia, alive, 760 days
15.0
TCGA-S6-A8JY-01A
27 years, male, white, stage:is, alive, 278 days
14.9
TCGA-2G-AAH3-01A
20 years, male, white, stage:i, alive, 1822 days
14.9
TCGA-XE-AANV-01A
52 years, male, stage:ib, alive, 1701 days
14.3
TCGA-ZM-AA0N-01A
44 years, male, white, stage:ib, alive, 634 days
14.0
TCGA-2G-AAF4-01A
30 years, male, white, stage:i, alive, 2315 days
13.8
TCGA-2G-AAGX-01A
22 years, male, white, stage:ia, alive, 5514 days
13.7
TCGA-2X-A9D6-01A
42 years, male, white, stage:i, alive, 607 days
13.5
TCGA-2G-AAFH-01A
38 years, male, white, stage:iib, alive, 1375 days
13.3
TCGA-YU-A90W-01A
45 years, male, white, stage:ia, alive, 1113 days
11.6
TCGA-ZM-AA0D-01A
34 years, male, white, stage:ia, alive, 848 days
11.6
TCGA-XE-AAOC-01A
31 years, male, white, stage:ia, alive, 270 days
10.9
TCGA-4K-AA1H-01A
26 years, male, white, stage:ia, alive, 518 days
10.8
TCGA-S6-A8JX-01A
27 years, male, white, stage:ib, alive, 552 days
10.0
TCGA-ZM-AA0H-01A
50 years, male, white, stage:is, alive, 1736 days
9.0
TCGA-XE-AAOL-01A
38 years, male, black or african american, stage:i, alive, 13 days
8.7
TCGA-ZM-AA0E-01A
39 years, male, white, stage:ia, alive, 811 days
8.5
TCGA-YU-A90S-01A
26 years, male, white, stage:ia, alive, 971 days
7.9
TCGA-ZM-AA0F-01A
35 years, male, white, stage:ia, alive, 681 days
7.6
TCGA-ZM-AA06-01A
45 years, male, white, stage:ib, alive, 1498 days
7.4
TCGA-2G-AAG6-01A
24 years, male, white, stage:is, alive, 2231 days
6.3
TCGA-2G-AAG5-01A
36 years, male, white, stage:is, alive, 2299 days
6.1
TCGA-ZM-AA05-01A
36 years, male, white, stage:iic, alive, 1126 days
6.0
TCGA-2G-AAGV-01A
23 years, male, white, alive, 4527 days
2.7
Show all
TESTIS CANCER - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off).
The Human Protein Atlas project is funded
MENU
